PPP
ORMP icon

Private Portfolio Partners’s Oramed Pharmaceuticals ORMP Stock Holding History

Private Portfolio Partners’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-53,600
Closed -$645K – 260
2022
Q4 		$645K Sell
53,600
-13,800
-20% -$107K 0.17% 108
2022
Q3 		$437K Buy
67,400
+13,390
+25% +$108K 0.12% 146
2022
Q2 		$247K Buy
54,010
+11,760
+28% +$62.8K 0.07% 225
2022
Q1 		$365K Buy
+42,250
New +$433K 0.09% 193

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SIGI
Susquehanna International Group (Ireland) Dublin, Ireland $472M AUM 25.62% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Private Portfolio Partners's ORMP Position: Q1 2023 in Review

Private Portfolio Partners sold out of Oramed Pharmaceuticals (ORMP) in Q1 2023, closing a stake of 53,600 shares — an estimated $645K sold.

Private Portfolio Partners first reported a position in ORMP in Q1 2022 and held it in 4 quarters. The position peaked at $645K in Q4 2022. 61 funds tracked by Wall St. Rank hold ORMP as of Q1 2023.

  • Private Portfolio Partners reported no remaining Oramed Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Private Portfolio Partners sold 53,600 Oramed Pharmaceuticals shares in Q1 2023, an estimated $645K.
  • Private Portfolio Partners first reported a position in Oramed Pharmaceuticals in Q1 2022 and held it in 4 quarters.
  • Private Portfolio Partners's Oramed Pharmaceuticals position peaked at $645K in Q4 2022.
  • 61 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2023.

Based on Private Portfolio Partners's 13F filing for Q1 2023, filed 12 May 2023.